Traders assign a 92.5% probability to no new COVID variant of concern before 2027 because circulating SARS-CoV-2 lineages, primarily JN.1 descendants such as XFG, NB.1.8.1, and BA.3.2, show incremental changes in transmissibility or immune escape without increased severity or public health impact. Recent FDA advisory recommendations for XFG-targeted 2026-2027 vaccines and WHO monitoring data indicate these variants under monitoring remain manageable amid high population immunity and lower hospitalization rates. Genomic surveillance gaps exist, yet no rapid emergence of a more dangerous strain has appeared in the past several months, supporting the view that a formal variant of concern designation is unlikely in the remaining months of 2026.